Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
2015 · Journal of Clinical Oncology · 183 citations
https://doi.org/10.1200/jco.2014.56.9590
J
Judith‐Anne W. Chapman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
63
Papers
957
Citations
16
h-index
22
i10-index
Judith‐Anne W. Chapman is an academic researcher from Canadian Cancer Society. The author has contributed to research in topics: Breast Cancer Treatment Studies & Cancer-related molecular mechanisms research & Estrogen and related hormone effects. The author has an h-index of 16, co-authored 54 publications.
Papers by this author
worksInnovative estimation of survival using log-normal survival modelling on ACCENT database
2013 · British Journal of Cancer · 20 citations
https://doi.org/10.1038/bjc.2013.34
Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
2007 · BMC Cancer · 15 citations
https://doi.org/10.1186/1471-2407-7-31
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
2015 · SpringerPlus · 10 citations
https://doi.org/10.1186/s40064-015-1392-x
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
2015 · British Journal of Cancer · 7 citations
https://doi.org/10.1038/bjc.2015.271
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14
2016 · Breast Cancer Research and Treatment · 1 citations
https://doi.org/10.1007/s10549-016-3806-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat